SG10201810886YA - Antibody titer-increasing agent using lactic acid bacterium - Google Patents

Antibody titer-increasing agent using lactic acid bacterium

Info

Publication number
SG10201810886YA
SG10201810886YA SG10201810886YA SG10201810886YA SG10201810886YA SG 10201810886Y A SG10201810886Y A SG 10201810886YA SG 10201810886Y A SG10201810886Y A SG 10201810886YA SG 10201810886Y A SG10201810886Y A SG 10201810886YA SG 10201810886Y A SG10201810886Y A SG 10201810886YA
Authority
SG
Singapore
Prior art keywords
antibody titer
increasing agent
lactic acid
acid bacterium
adjuvant
Prior art date
Application number
SG10201810886YA
Inventor
Seiya Makino
Jun Henmi
Hiroshi Kano
Yukio Asami
Shuji Ikegami
Hiroyuki Itou
Yoshio Suzuki
Sachio Kawai
Keisuke Sawaki
Ko Okumura
Isao Nagaoka
Kazuyoshi Takeda
Original Assignee
Meiji Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Co Ltd filed Critical Meiji Co Ltd
Publication of SG10201810886YA publication Critical patent/SG10201810886YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

ANTIBODY TITER-INCREASING AGENT USING LACTIC ACID BACTERIUM The present invention addresses the problem of providing an 5 antibody titer-increasing agent, such as an adjuvant, capable of sustaining an effect achieved by, for example, vaccination, which is an antibody titer-increasing agent such as an adjuvant that is safe, convenient and economical and can be easily taken irrespective of age, and a method for manufacturing the same; a 10 method for increasing an antibody titer and a method for enhancing the effect of a vaccine, each method comprising using Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 or a culture thereof; and an antibody titer-increasing agent such as an adjuvant that comprises Lactobacillus delbrueckii ssp. bulgaricus OLL1073R-1 or 15 a culture thereof. [No suitable figure]
SG10201810886YA 2013-08-26 2014-08-26 Antibody titer-increasing agent using lactic acid bacterium SG10201810886YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013175048 2013-08-26

Publications (1)

Publication Number Publication Date
SG10201810886YA true SG10201810886YA (en) 2019-01-30

Family

ID=52586524

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201810886YA SG10201810886YA (en) 2013-08-26 2014-08-26 Antibody titer-increasing agent using lactic acid bacterium
SG11201601185YA SG11201601185YA (en) 2013-08-26 2014-08-26 Antibody titer-increasing agent using lactic acid bacterium

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11201601185YA SG11201601185YA (en) 2013-08-26 2014-08-26 Antibody titer-increasing agent using lactic acid bacterium

Country Status (10)

Country Link
US (1) US10195271B2 (en)
EP (1) EP3040083B1 (en)
JP (1) JP6449771B2 (en)
CN (1) CN105555307A (en)
AU (1) AU2014313030B2 (en)
CA (1) CA2921820C (en)
HK (1) HK1218387A1 (en)
NZ (1) NZ717369A (en)
SG (2) SG10201810886YA (en)
WO (1) WO2015029967A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6713751B2 (en) * 2015-10-26 2020-06-24 キリンホールディングス株式会社 Method for enhancing specific cytotoxic T cell (CTL) and antibody production against antigen
JP6777911B2 (en) * 2016-08-17 2020-10-28 株式会社明治 Fermented milk for suppressing the decrease in immune function acquired by anti-influenza drugs and its manufacturing method
JP7065589B2 (en) * 2017-10-31 2022-05-12 株式会社明治 Fermented milk for lowering IL-1β serum concentration, fermented milk for lowering CXCL1 serum concentration, fermented milk for suppressing excessive increase in serum concentration of IL-1β associated with cancer, or suppressing excessive increase in serum concentration of CXCL1 associated with cancer. Fermented milk for
US20220362303A1 (en) * 2021-02-26 2022-11-17 Pantheryx, Inc. Stabilized colostrum compositions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2911057B2 (en) 1991-01-18 1999-06-23 高砂香料工業株式会社 Infection protective agents and functional foods having an infection protective effect
JP3805572B2 (en) * 1999-07-27 2006-08-02 大和製罐株式会社 Easy to crush plastic bottle
JP5177728B2 (en) 2003-12-12 2013-04-10 株式会社明治 NK cell activator
JP3975361B2 (en) * 2004-03-08 2007-09-12 愛媛県 Anti-Streptococcus thermophilus monoclonal antibody, production cell thereof, detection method and detection reagent for Streptococcus thermophilus
ATE473636T1 (en) 2005-02-15 2010-07-15 Barry R Goldin FOODS CONTAINING PROBIOTIC AND ISOLATED BETA-GLUCAN AND METHOD OF USE THEREOF
FR2912657B1 (en) * 2007-02-16 2009-04-17 Gervais Danone Sa USE OF LACTOBACILLUS CASEI TO ENHANCE PROTECTION INDUCED BY ANTI-INFLUENZA VACCINATION.
JP5971949B2 (en) 2009-11-25 2016-08-17 株式会社明治 Antiviral agent
JP5242855B2 (en) 2010-07-29 2013-07-24 国立大学法人北海道大学 Immune adjuvant
US20130195917A1 (en) 2010-10-15 2013-08-01 Dorte Eskesen Immunoadjuvant

Also Published As

Publication number Publication date
NZ717369A (en) 2017-11-24
US10195271B2 (en) 2019-02-05
JP6449771B2 (en) 2019-01-09
EP3040083A1 (en) 2016-07-06
CN105555307A (en) 2016-05-04
WO2015029967A1 (en) 2015-03-05
EP3040083A4 (en) 2017-01-18
CA2921820C (en) 2021-10-12
CA2921820A1 (en) 2015-03-05
AU2014313030A1 (en) 2016-04-07
EP3040083B1 (en) 2018-11-21
US20160206733A1 (en) 2016-07-21
AU2014313030B2 (en) 2017-01-19
JPWO2015029967A1 (en) 2017-03-02
SG11201601185YA (en) 2016-03-30
HK1218387A1 (en) 2017-02-17

Similar Documents

Publication Publication Date Title
SG10201809694PA (en) Antibody neutralizing human respiratory syncytial virus
PH12014502855B1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
SG10201810886YA (en) Antibody titer-increasing agent using lactic acid bacterium
AR105868A1 (en) BACTERIAS LACTOBACILLUS FERMENTUM THAT REDUCE THE CONCENTRATION OF ACETALDEHYDE
NZ715459A (en) A hyperbarically-inactivated microorganism, immunogenic compositions comprising same and methods for producing same
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
NZ741342A (en) Daptomycin formulations and uses thereof
MX349657B (en) Protein matrix vaccine compositions including polycations.
MY191217A (en) Group a streptococcus vaccine
WO2013188673A3 (en) Reassortant btv and ahsv vaccines
MX2016016885A (en) In ovo delivery of probiotic cultures.
PH12015502844A1 (en) Mammalian milk osteopontin for enhancing immune responsiveness
PH12019502239A1 (en) Lactic acid bacteria, methods and uses thereof
EP4316497A3 (en) Mesenchymal stem cells as vaccine adjuvants and methods for using the same
WO2012009774A3 (en) Recombinant microorganisms, methods for preparing vaccine strains, antigens, and vector vaccine compositions of same, uses thereof, and related antibodies, diagnostic kit, and treatment and/or prophylactic methods
GB2515222A (en) Use of flagellin as a vaccine
MX2019005535A (en) Streptococcus thermophilus for use in preparation of fermented products.
CL2013001791A1 (en) Method for the production of a dairy product comprising lactococcus lactis subsp. lactis biovar. diacetylactis; fermented milk product; use of said bacterium to impart at least one malt flavor and aroma to the milk source.
EA201891508A1 (en) COMPOSITIONS AND METHODS OF APPLICATION OF NEW STRAINS LACTOBACILLUS FERMENTUM
WO2011112906A3 (en) Novel immunogens and methods for discovery and screening thereof
WO2013173256A3 (en) New and improved influenza vaccines
PH12017500407A1 (en) Streptococcus agalactiae antigens associated with strains virulent in fish
TH182464A (en) An active substance that increases an antibody titer by the use of lactic acid bacterium-producing bacteria.
PL409072A1 (en) 4-ethoxy-4'-methoxy α,β-dihydrochalcone and method for obtaining 4-ethoxy-4'-methoxy α.β-dihydrochalcone